Figure 6

Everolimus decreases the T ₁ and bioluminescence of cervical B16/BL6 melanoma metastases. C57/BL6 mice bearing B16/BL6 melanomas were treated with everolimus (10 mg/kg/day) or vehicle for 6 days and the spin–lattice relaxation of protons (T₁) in tumours was measured on day 0 and at the endpoint day 6. Lymph-nodes were removed and extracted for measurement of bioluminescence (BioL) as described in Methods. Results show the mean ± SEM, and the individual T₁ values (A) and bioluminescence (C), the fractional change in T₁ (ΔT₁) for the treatments (B), and the Pearson correlations (with the associated r and p values) between BioL and ΔT₁ (D), where **p < 0.01, ***p < 0.001 as shown.